as 10-17-2024 4:00pm EST
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
Founded: | 2002 | Country: | United States |
Employees: | N/A | City: | PRINCETON |
Market Cap: | 27.2M | IPO Year: | N/A |
Target Price: | $10.00 | AVG Volume (30 days): | 23.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.10 | EPS Growth: | N/A |
52 Week Low/High: | $1.98 - $3.59 | Next Earning Date: | 11-11-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
ACST Breaking Stock News: Dive into ACST Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
Zacks
3 months ago
Simply Wall St.
4 months ago
The information presented on this page, "ACST Acasti Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.